Story perspectives

Libtayo Approved for Advanced NSCLC Reimbursement in Québec

11/1/2025

50 11

Summary

Story summary

Regeneron Canada says Libtayo (cemiplimab) is reimbursed by Québec's RAMQ for adults with advanced NSCLC.
The coverage applies to tumors with specific characteristics and to patients unsuitable for surgery or chemoradiation.
Libtayo is also reimbursed in several other Canadian provinces for advanced NSCLC and locally advanced basal cell carcinoma.
Regeneron states Libtayo blocks the PD-1 pathway to boost T-cell responses and aims to transform cancer therapy with a broad pipeline.

1 of 1

Story summary

Regeneron Canada says Libtayo (cemiplimab) is reimbursed by Québec's RAMQ for adults with advanced NSCLC.
The coverage applies to tumors with specific characteristics and to patients unsuitable for surgery or chemoradiation.
Libtayo is also reimbursed in several other Canadian provinces for advanced NSCLC and locally advanced basal cell carcinoma.
Regeneron states Libtayo blocks the PD-1 pathway to boost T-cell responses and aims to transform cancer therapy with a broad pipeline.